Skip to main content
Leonard Farber, MD, Radiation Oncology, Long Beach, CA, NewYork-Presbyterian/Lower Manhattan Hospital

LeonardAFarberMD

Radiation Oncology Long Beach, CA

Breast Cancer, Gastrointestinal Cancer, Head & Neck, Skin Cancer

Chief Clinical and Medical Affairs Officer

Dr. Farber is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Farber's full profile

Already have an account?

Summary

  • I am a Board Certified physician in Radiation Oncology. I have been in private practice for over a decade, recently opened and founded The Farber Center for Radiation Oncology in Tribeca NYC. Before I opened The Farber Center, I served as Chairman of Radiation Oncology at Staten Island University Hospital. I specialize in adult radiation oncology, with particular focus on breast cancer, prostate cancer and gastrointestinal malignancies, lymphomas, head and neck cancers and lung cancers. I am an expert in HDR brachytherapy for various types of cancers, including breast, skin and gynecologic malignancies, and intracranial and body radiosurgery.

    After receiving my B.S. and B.A. at the State University of New York at Binghamton, I pursued my M.D. at the Mt. Sinai School of Medicine in New York. Following an internship in internal medicine at Beth Israel Medical Center in New York, I did my residency in Radiation Oncology at the Hospital of the University of Pennsylvania in Philadelphia, where I served as Chief Resident. I am a member of the American Society for Therapeutic Radiology and Oncology, the American College of Radiation Oncology, the American Radium Society, the American Brachytherapy Society, the New York Cancer Society, the New York Metropolitan Breast Cancer Group, the New York Head & Neck Society, and the Long Island Oncology Network.

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemChief Residency, Radiation Oncology, 1997 - 1998
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Radiation Oncology, 1995 - 1997
  • Icahn School of Medicine at Mount Sinai (Beth Israel)
    Icahn School of Medicine at Mount Sinai (Beth Israel)Internship, Internal Medicine, 1994 - 1995
  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiClass of 1994, MD
  • State University of New York
    State University of New YorkBS/BA, 1990

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2017 - 2025
  • NY State Medical License
    NY State Medical License 1998 - 2025
  • LA State Medical License
    LA State Medical License 2021 - 2023
  • MI State Medical License
    MI State Medical License 2020 - 2023
  • NJ State Medical License
    NJ State Medical License 2010 - 2019
  • PA State Medical License
    PA State Medical License 1996 - 2016
  • CT State Medical License
    CT State Medical License 2009 - 2013
  • American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

  • Super Doctors Super Doctors, 2012
  • Best Doctors Best Doctors, 2012
  • America’s Top Oncologists Award in Radiation Oncology Consumers Research Council of America (2005) (2009) (2010), 2011
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Comparison of Conventional Versus Conformal External Bean Irradiation of a Stented Coronary Artery Utilizing a New Fluoroscopic Imaging Detector System.  
    Farber LA, Bloch P, York ED, Stevens CW, Herrmann H, Ruffer J, Cardiovascular Radiation Medicine 1(1): 1999;80-85
  • Detection of Recurrent Head and Neck Squamous Cell Carcinomas after Radiation Therapy with 218-F-Fluoro-2deoxy-D-glucose Positron Emission Tomography.  
    Farber LA, Bernard F, Machtay M, Alavi A, Smith RJ, Weber RS, Weinstein GS, Rosenthal DI, Laryngoscope 109: 1999;970-975
  • Dual Time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the ...  
    Hustinx R, Smith RJ, Bernard F, Rosenthal DI, Machtay M, Farber LA, Alavi A, European Journal of Nuclear Medicine, 26: 1999;1345-1348
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Time and Outcome Commitment Utilizing Beta-Irradiation Source Delivery Systems.
    Farber LA, Shlofmitz RA, Haag ES, Speck T, Berke A, Proceedings of the Scripps Clinic and Research Foundation- Fourth Annual Symposium on Radiotherapy t
  • Utility Of The Contrast Enhanced MRI Processed With ProStream Software In The Evaluation Of The Patients Previously Treated For Prostate Carcinoma With New Rise In PSA.
    Berkovich GY, Badillo F, Waldbaum R, Farber LA, Edelman RA, Bosworth J, Pollack J, American Urological Association New York Section 105th Annual Meeting
  • The use of Position Emission Tomography Imaging with 2-18-F-fluoro-2-deoxy-D-glucose to distinguish post-radiation effects from tumorpersistence/recurrences from in he...
    Farber LA, Nguyen K, Alavi A, Machtay M, Weinstein GS, Chalian AA, Weber RS, Rosenthal DT, Proceedings of American Radium Society
  • Join now to see all

Lectures

  • Endorectal High Dose-Rate Brachytherapy: A preoperative downstaging treatment modality for patients with locally advanced rectal cancer. 
    American Brachytherapy Society Annual Meeting, Toronta, Ontario, Canada
  • Radiation Therapy and Treatment of Endometrial Cancer. 
    Grand Rounds, Department of Gynecology Staten Island, University Hospital
  • Innovations in Radiation Oncology. 
    Grand Rounds, Department of Medicine, Staten Island University Hospital
  • Join now to see all

Other

  • Utilization of a diagnostic related group (DRG) computer system to analyze the frequency of thromboembolic complications in solid tumor malignancies. 
    Farber LA, DiGiovanni G, Bruckner HW, OncoLink
    http://www.oncolink.upenn.edu

Press Mentions

  • NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer
    NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic CancerNovember 14th, 2022
  • NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 plus Anti-PD-1 for Patients with Advanced Cancers
    NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 plus Anti-PD-1 for Patients with Advanced CancersJuly 20th, 2023

Other Languages

  • Spanish, Chinese (Mandarin), Russian, Chinese (Cantonese)

Hospital Affiliations